Elevance Health, Inc. $ELV Stock Sold by Lawson Kroeker Investment Management Inc. NE

Lawson Kroeker Investment Management Inc. NE lessened its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 7.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 22,446 shares of the company’s stock after selling 1,753 shares during the period. Elevance Health makes up about 2.7% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 15th largest holding. Lawson Kroeker Investment Management Inc. NE’s holdings in Elevance Health were worth $8,727,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Elevance Health in the 2nd quarter valued at approximately $7,344,424,000. Bank of New York Mellon Corp bought a new stake in Elevance Health during the second quarter worth approximately $1,246,349,000. Legal & General Group Plc bought a new stake in Elevance Health during the second quarter worth approximately $688,469,000. Amundi grew its holdings in Elevance Health by 145.7% during the first quarter. Amundi now owns 2,693,664 shares of the company’s stock valued at $788,570,000 after purchasing an additional 1,597,497 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Elevance Health during the second quarter valued at approximately $591,084,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Analyst Ratings Changes

ELV has been the topic of a number of recent analyst reports. Leerink Partners lifted their price target on shares of Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research report on Friday, July 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $451.00 price objective on shares of Elevance Health in a report on Friday. Barclays raised their target price on shares of Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a research note on Thursday. Raymond James Financial set a $450.00 target price on shares of Elevance Health in a report on Tuesday, July 7th. Finally, UBS Group boosted their target price on shares of Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research report on Thursday. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $455.57.

Elevance Health Stock Performance

ELV opened at $440.05 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock’s 50 day moving average price is $408.32 and its two-hundred day moving average price is $390.89. The firm has a market capitalization of $95.43 billion, a P/E ratio of 18.77, a price-to-earnings-growth ratio of 2.32 and a beta of 0.70. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same period in the previous year, the company earned $6.03 earnings per share. The company’s quarterly revenue was up .7% compared to the same quarter last year. On average, equities analysts forecast that Elevance Health, Inc. will post 27.09 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s payout ratio is 29.34%.

Insider Buying and Selling

In related news, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares in the company, valued at $8,766,949.47. This represents a 34.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is currently owned by insiders.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.